Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
The content in this section is aimed at anyone involved in planning, implementing or making decisions about health and social responses.
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
Explore our wide range of publications, videos and infographics on the drugs problem and how Europe is responding to it.
We are your source of drug-related expertise in Europe. We prepare and share independent, scientifically validated knowledge, alerts and recommendations.
The extended Scientific Committee of the EMCDDA meets on 18-19 November 2021 to examine the risk assessment by the EMCDDA of the new psychoactive substances 3-MMC and 3_CMC.
